Squalamine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Squalamine
Accession Number
DB06461
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
MSI-1246
Product Ingredients
IngredientUNIICASInChI Key
Squalamine lactate4WE915J1KX320725-47-1ZPYIELFRIYUVQP-BHBJEIPNSA-N
International/Other Brands
Evizon
Categories
UNII
F8PO54Z4V7
CAS number
148717-90-2
Weight
Average: 627.97
Monoisotopic: 627.464493379
Chemical Formula
C34H65N3O5S
InChI Key
UIRKNQLZZXALBI-MSVGPLKSSA-N
InChI
InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
IUPAC Name
{[(3R,6R)-6-[(1S,2S,5S,7R,9R,10R,11S,14R,15R)-5-({3-[(4-aminobutyl)amino]propyl}amino)-9-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2-methylheptan-3-yl]oxy}sulfonic acid
SMILES
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O

Pharmacology

Indication

Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Squalamine is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Squalamine is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Squalamine is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Squalamine is combined with Acenocoumarol.
Alendronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Alendronic acid.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Squalamine.
Clodronic acidThe risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Clodronic acid.
ClorindioneThe risk or severity of bleeding can be increased when Squalamine is combined with Clorindione.
CoumarinThe risk or severity of bleeding can be increased when Squalamine is combined with Coumarin.
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Squalamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Williams JI, Weitman S, Gonzalez CM, Jundt CH, Marty J, Stringer SD, Holroyd KJ, Mclane MP, Chen Q, Zasloff M, Von Hoff DD: Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies. Clin Cancer Res. 2001 Mar;7(3):724-33. [PubMed:11297269]
External Links
KEGG Compound
C16841
ChemSpider
65407
ChEBI
80765
ChEMBL
CHEMBL444929
ZINC
ZINC000030160243
Wikipedia
Squalamine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentMacular Edema / Retinal Vein Occlusion1
2CompletedTreatmentNeovascular Age Related Macular Degeneration / Neovascular Age-Related Macular Degeneration1
2CompletedTreatmentRetinal Neovascularization1
2TerminatedNot AvailableMacular Degeneration1
2TerminatedTreatmentMacular Degeneration2
2Unknown StatusTreatmentOvarian Cancer1
2WithdrawnTreatmentAge-Related Macular Degeneration (ARMD)1
2WithdrawnTreatmentDiabetic Retinopathy (DR)1
2WithdrawnTreatmentProstate Cancer1
3Active Not RecruitingTreatmentAge-Related Macular Degeneration (ARMD)1
3TerminatedTreatment"Wet" Age-Related Macular Degeneration / Wet Age-Related Macular Degeneration1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000169 mg/mLALOGPS
logP2.48ALOGPS
logP3.24ChemAxon
logS-6.6ALOGPS
pKa (Strongest Acidic)-1.3ChemAxon
pKa (Strongest Basic)10.89ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area133.91 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity174.42 m3·mol-1ChemAxon
Polarizability77.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as monohydroxy bile acids, alcohols and derivatives. These are bile acids, alcohols or any of their derivatives bearing a hydroxyl group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Bile acids, alcohols and derivatives
Direct Parent
Monohydroxy bile acids, alcohols and derivatives
Alternative Parents
Pregnane-type alkaloids / 7-hydroxysteroids / Azasteroids and derivatives / Sulfated steroids / Alkaloids and derivatives / Sulfuric acid monoesters / Alkyl sulfates / Secondary alcohols / Cyclic alcohols and derivatives / Dialkylamines
show 4 more
Substituents
Monohydroxy bile acid, alcohol, or derivatives / Sulfated steroid skeleton / Steroidal alkaloid / Pregnane-type alkaloid / Hydroxysteroid / 7-hydroxysteroid / Azasteroid / Alkaloid or derivatives / Sulfuric acid ester / Alkyl sulfate
show 19 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
bile acid (CHEBI:80765) / Marine nature products (C16841)

Drug created on March 19, 2008 10:34 / Updated on March 02, 2020 00:01

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates